Cipla Ltd. — Regulatory Filings 2020

Oct 28, 2020

28[th] October 2020

(1) BSE Ltd (2) National Stock Exchange of India Ltd Listing Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5[th] floor, Dalal Street, Plot no. C/1, G Block, Mumbai - 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Scrip Code: 500087 Scrip Code: CIPLA EQ

• (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Sub: Press Release - Cipla launches ‘ELIFast’ (IgG ELISA test) for COVID-19 antibody

detection

Dear Sir / Madam,

Please find enclosed press release dated 28[th] October 2020 for the captioned subject.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking you,

Yours faithfully, For Cipla Limited Digitally signed by RAJENDRA CHOPRA RAJENDR DN: c=IN, o=Personal, 2.5.4.20=4987ad48c3965cfde78c8ea69e 6f40ac91535876f12ba1fa5ba45cc5cc8d b6cb, postalCode=122001, A st=HARYANA, serialNumber=0be85c0408d0e3afd6636 69f5314248a72fdcdf34d01d48d472d7cf 9262696f6, cn=RAJENDRA CHOPRA CHOPRA Date: 2020.10.28 16:02:20 +05'30' Rajendra Chopra Company Secretary

Encl.as above

Prepared by: Juzer Masta

Press Release

==> picture [90 x 49] intentionally omitted <==

Cipla launches ‘ELIFast’ (IgG ELISA test) for COVID-19 antibody

detection

• Cipla to market ICMR approved IgG ELISA testing kit in India

Mumbai, India; October 28, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla,” today announced the commercialisation of antibody detection kits for COVID-19 in India. In partnership with KARWA Ltd. under the technology transfer from the Indian Council of Medical Research (ICMR).

As part of this collaborative effort, Cipla will be responsible for the marketing and distribution of the SARS CoV-2-IgG antibody detection ELISA that will be manufactured by KARWA Ltd. ICMR has provided the requisite technological know-how and process for developing the test kits to the approved manufacturers. The product will be marketed under the brand name ‘ELIFast’. Cipla’s expansive distribution network will help in ensuring the seamless supply of kits across the country. Supply will be undertaken through the channels approved by ICMR, to ensure equitable access.

IgG Antibody tests identify the immune status of the individuals to the COVID-19 infection. ICMR has recommended these tests for conducting sero-surveillance. Serosurveillance may help in determining the burden of COVID-19 at the community level and monitor the trends in the transmission of SARS-CoV-2 infection.

ELIfast has been validated and approved by ICMR and the National Institute of Virology (NIV), Pune. It is found to have specificity and sensitivity of 99.33% and 92% respectively. The kit is user friendly with a simple protocol with ready-to-use reagents and is compatible with common ELISA equipment.

==> picture [455 x 64] intentionally omitted <==

==> picture [584 x 65] intentionally omitted <==

==> picture [90 x 49] intentionally omitted <==

==> picture [455 x 32] intentionally omitted <==

About Cipla :

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3[rd] largest in pharma in India (IQVIA MAT September’ 20), 3[rd] largest in the pharma private market in South Africa (IQVIA MAT September’20), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

For queries, please contact :

Corporate Communications Investor Relations

Heena Kanal Naveen Bansal E-Mail: CorpComm@cipla.com E-Mail: Investor.Relations@cipla.com

==> picture [584 x 65] intentionally omitted <==